Preventing Coronavirus Disease 2019 in Kidney Transplant Recipients: Where Should We Begin?

Context: Chronic immunosuppression is associated with an increased risk of opportunistic infections. Although kidney transplant recipients with coronavirus disease 2019 (COVID-19) have higher mortality than the general population, data on their risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are unknown. Subject of Review: A recent single-center screening study from the UK (Transplantation. 2021 Jan 1;105(1):151–7) showed that 89 (10.4%) of 855 consecutive kidney transplant recipients tested positive for SARS-CoV-2 antibodies. Risk factors for infection included a nonwhite background, diabetes, and a history of allograft rejection. Risk factors for mortality in individuals who developed COVID-19 were older age and receiving steroids. Second Opinion: This study shows that the rate of SARS-CoV-2 infection in kidney transplant recipients is similar to the one observed in the general population in the same area (13%), indicating that transplant recipients are not at increased risk of COVID-19. However, the investigators raise the interesting point that since transplant individuals were advised to shelter earlier than the general population, they may be in fact more susceptible. This statement is hard to substantiate, but the identification of specific risk factors for infection and poor outcomes is crucial to tailor strategies to prevent spread of the infection. This is particularly important, considering that kidney transplant recipients may be at increased risk of prolonged viral spread and in-host viral mutations, making them not just a particularly fragile population for COVID-19 but also a potentially major source of further contagions.

[1]  D. Segev,et al.  Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. , 2021, JAMA.

[2]  G. Lucisano,et al.  Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening. , 2020, Transplantation.

[3]  E. Fischer,et al.  Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer , 2020, Cell.

[4]  L. Greathead,et al.  Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients. , 2020, Journal of the American Society of Nephrology : JASN.

[5]  Vineet D. Menachery,et al.  Spike mutation D614G alters SARS-CoV-2 fitness , 2020, Nature.

[6]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[7]  R. Baric,et al.  Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.

[8]  K. Khunti,et al.  Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study , 2020, The Lancet Diabetes & Endocrinology.

[9]  P. Cravedi,et al.  Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients , 2020, American Journal of Transplantation.

[10]  T. Hallett,et al.  Clinical Characteristics and Predictors of Outcomes of Hospitalized Patients With Coronavirus Disease 2019 in a Multiethnic London National Health Service Trust: A Retrospective Cohort Study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Schold,et al.  The COVID‐19 pandemic: A community approach , 2020, Clinical transplantation.

[12]  M. Cescon,et al.  COVID‐19 in solid organ transplant recipients: No difference in survival compared to general population , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[13]  U. Maggiore,et al.  COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium , 2020, American Journal of Transplantation.

[14]  D. Lauffenburger,et al.  Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production , 2020, Cell.

[15]  A. Sette,et al.  The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.

[16]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[17]  L. Trupin,et al.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.

[18]  Laura C Myers,et al.  Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. , 2020, JAMA.

[19]  E. Akalin,et al.  Covid-19 and Kidney Transplantation , 2020, The New England journal of medicine.

[20]  Nathaniel Hupert,et al.  Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.

[21]  David W. Johnson,et al.  Infection-Related Mortality in Recipients of a Kidney Transplant in Australia and New Zealand: Infection-related mortality in kidney transplant recipients. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[22]  S. Arora,et al.  Vaccinations in kidney transplant recipients: Clearing the muddy waters , 2019, World journal of transplantation.

[23]  Michael Green,et al.  Introduction: Infections in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  U. Maggiore,et al.  COVID-19 in kidney transplant recipients , 2020, American Journal of Transplantation.